Research Topics
| P E MorrisSummaryAffiliation: Wake Forest University School of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Acute respiratory distress syndrome: pharmacological treatment options in developmentR D Hite
Section on Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Drugs 61:897-907. 2001....- A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adultsPeter E Morris
Pulmonary Critical Care, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Crit Care 14:R125. 2010..Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults... - Early intensive care unit mobility therapy in the treatment of acute respiratory failurePeter E Morris
Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University School of Medicine, Winston Salem, NC, USA
Crit Care Med 36:2238-43. 2008..Despite the theoretical advantages of physical therapy to address this problem, it has not been shown that physical therapy initiated in the intensive care unit offers benefit... - Receiving early mobility during an intensive care unit admission is a predictor of improved outcomes in acute respiratory failurePeter E Morris
Pulmonary, Critical Care, Allergy and Immunologic Disease, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Am J Med Sci 341:373-7. 2011.... - Early intensive care unit mobility: future directionsPeter E Morris
Section on Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest University School of Medicine, Gray Building, Room 3141, Medical Center Boulevard, Winston Salem, NC 27157, USA
Crit Care Clin 23:97-110. 2007..Finally, we present a "roadmap" outlining future directions moving toward the development and testing of early ICU mobility therapies... - Moving our critically ill patients: mobility barriers and benefitsPeter E Morris
Pulmonary Medical, Room 3141 Gray Building, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Crit Care Clin 23:1-20. 2007..This article focuses particularly on how mobilization may improve quality of life for patients... - Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated)Peter E Morris
Pulmonary Medicine, Wake Forest University School of Medicine, 3rd Floor, Gray Building, 3325 Silas Creek Parkway, Winston Salem, NC 27103, USA
Am J Surg 184:S19-24. 2002.... - Drotrecogin alfaMichael J Raggio
Pulmonary and Critical Care Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA
Drugs Today (Barc) 40:517-38. 2004..A phase III clinical trial has demonstrated reduced mortality in severe sepsis patients receiving activated protein C... - Comparison of 3 methods of detecting acute respiratory distress syndrome: clinical screening, chart review, and diagnostic codingApril E Howard
Wake Forest University School of Medicine, Winston-Salem, NC, USA
Am J Crit Care 13:59-64. 2004..Both physicians and medical record coding specialists may require training in use of terms related to acute respiratory distress syndrome... - A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndromePeter E Morris
Department of Pulmonary Critical Care, Wake Forest University School of Medicine, Winston Salem, NC, USA
Crit Care Med 36:782-8. 2008..We examined the efficacy and safety of oxothiazolidine-4-carboxylic acid (OTZ), a free radical scavenger, in treating acute respiratory distress syndrome... - Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein CPeter E Morris
Division of Pulmonary and Critical Care Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27104, USA
BioDrugs 16:403-17. 2002..A phase III clinical trial has now demonstrated reduced mortality in patients with severe sepsis receiving activated protein C... - Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated)Peter E Morris
Am J Crit Care 12:94-7. 2003 - Could multicenter trials optimize the cost of prolonged mechanical ventilation?Peter E Morris
Am J Crit Care 17:8-10. 2008 - Foundations of evidence-based practice: critical care trial networksPeter E Morris
Am J Crit Care 17:190-3. 2008 - Passing the torch: the challenge of handoffsKathleen Dracup
Am J Crit Care 17:95-7. 2008 - Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsisTodd W Rice
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
Crit Care Med 34:2271-81. 2006..CONCLUSIONS: CytoFab is well tolerated in patients with severe sepsis, effectively reducing serum and BAL TNF-alpha and serum IL-6 concentrations and increasing the number of ventilator-free and ICU-free days at day 28... - Nurse residency programs: preparing for the next shiftKathleen Dracup
Am J Crit Care 16:328-30. 2007 - Critical care professionalism in the age of pay-for-performance: from ICUs to outpatient critical care clinicsPeter E Morris
Am J Crit Care 16:200-3. 2007
Research Grants
- Standardized Rehabilitation for ICU Patients with Acute Respiratory FailurePeter Morris; Fiscal Year: 2009....
- Standardized Rehabilitation for ICU Patients with Acute Respiratory FailurePeter E Morris; Fiscal Year: 2010....